# US 2022/0033388 A1 · HDAC1,2 Inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0033388 A1
- Document ID: US20220033388A1
- Status: Published application
- Kind: A1
- Application number: 17/278,485
- Filed: 2019-09-25
- Published: 2022-02-03
- Earliest claimed: 2018-09-25
- Assignees: Regenacy Pharmaceuticals, LLC
- Applicants: Regenacy Pharmaceuticals, LLC
- Inventors: John H. VAN DUZER; Ralph MAZITSCHEK; Charles BLUM
- Web page: https://patentgrep.com/patent/US20220033388A1

## CPC

- C07D 409/12: linked by a chain containing hetero atoms as chain links
- C07D 209/34: in position 2
- C07D 235/08: Radicals containing only hydrogen and carbon atoms
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 405/12: linked by a chain containing hetero atoms as chain links
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Provided herein are compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat diseases or disorders associated with HDAC1 and/or HDAC2 activity.

## Claims

### Claim 1

A compound of Formula I:
or a pharmaceutically acceptable salt thereof;
wherein:
R1 is selected from the group consisting of aryl or heteroaryl, wherein aryl or heteroaryl are optionally substituted with —OH or —OSO2NHCH3;
R2 is selected from the group consisting of —H, C1-C6 alkyl, alkyl-cycloalkyl, alkyl-heterocycloalkyl, alkyl-aryl, alkyl-heteroaryl, aryl, heteroaryl, and halo; and
R3 and R4 are independently, at each occurrence, selected from the group consisting of —H, halo, alkyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl.

### Claim 2 (depends on 1)

The compound of claim 1, wherein:
R1 is selected from the group consisting of phenyl, phenyl-OH, phenyl-OSO2NHMe, thienyl, and furanyl;
R2 is selected from the group consisting of —H, methyl, —CH2-cyclopropyl, and C1-C3 alkyl-5-6 membered heterocycloalkyl; and
R3 and R4 are independently, at each occurrence, selected from the group consisting of —H, halo, and methyl.

### Claim 3

A compound of Formula II:
or a pharmaceutically acceptable salt thereof;
wherein:
R1 is selected from the group consisting of aryl and heteroaryl, wherein aryl or heteroaryl are optionally substituted with —OH or —OSO2NHCH3;
R2 is selected from the group consisting of absent, —H, C1-C6 alkyl, alkyl-cycloalkyl, alkyl-heterocycloalkyl, aryl, and heteroaryl;
R3 is selected from the group consisting of absent, —H, C1-C6 alkyl, alkyl-cycloalkyl, alkyl-heterocycloalkyl, aryl, and heteroaryl;
R4 is selected from the group consisting of —H, —OH, alkyl, aryl, cycloalkyl, and heteroaryl; and
indicates an optional double bond.

### Claim 4 (depends on 3)

The compound of claim 3, wherein:
R1 is phenyl or thienyl;
R2 is selected from the group consisting of absent, —H, methyl, and C2-alkyl-5-6 membered heterocycloalkyl;
R3 is selected from the group consisting of absent, —H, and —C2-alkyl-5-6 membered heterocycloalkyl; and
R4 is selected from the group consisting of —H, cyclopropyl, and methyl.

### Claim 5 (depends on 1, 2, 3, 4)

The compound of any of claims 1-4, wherein the compound of Formula I or Formula II is selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.

### Claim 6

A compound of Formula III:
or a pharmaceutically acceptable salt thereof;
wherein:
X and Y are, independently at each occurrence, selected from the group consisting of CH and N, provided at least one of X and Y are N;
R1 is —N(R4)2 or —OR4;
R2 is selected from the group consisting of halo, aryl, and heteroaryl, wherein aryl or heteroaryl are optionally substituted by one or more R5;
R3 is independently, at each occurrence, selected from the group consisting of halo, cycloalkyl, heterocycloalkyl, —N(R6)—C1-C3 alkyl-N(R6)2, —O—C1-C3 alkyl-N(R6)2, and —N(R6)—C1-C3 alkyl-OR6, wherein cycloalkyl and heterocycloalkyl are optionally substituted by one or more R5;
R4 is independently, at each occurrence, selected from the group consisting of —H, C1-C6 alkyl, and C1-C6 alkoxy;
R5 is independently, at each occurrence, —H or C1-C6 alkyl;
R6 is independently, at each occurrence, selected from the group consisting of —H, C1-C6 alkyl, and C1-C6 alkoxy; and
n is 0, 1, 2, or 3.

### Claim 7 (depends on 6)

The compound of claim 6, wherein
R1 is —NH2 or —OH;
R2 is halo or heteroaryl, wherein heteroaryl is optionally substituted by one or more R5;
R3 is independently, at each occurrence, selected from the group consisting of cycloalkyl, heterocycloalkyl, —N(R6)—C1-C3 alkyl-N(R6)2, —O—C1-C3 alkyl-N(R6)2, and —N(R6)—C1-C3 alkyl-OR6, wherein cycloalkyl and heterocycloalkyl are optionally substituted by one or more R5;
R4 is independently, at each occurrence, —H or C1-C6 alkyl;
R5 is independently, at each occurrence, —H or C1-C6 alkyl;
R6 is independently, at each occurrence, —H or C1-C6 alkyl;
and n is 1, 2, or 3.

### Claim 8 (depends on 6)

The compound of claim 6, wherein the compound of Formula III is a compound of Formula IV:
or a pharmaceutically acceptable salt thereof.

### Claim 9 (depends on 6, 7, 8)

The compound of any one of claims 6-8, wherein R3 is independently, at each occurrence, selected from the group consisting of cycloalkyl, heterocycloalkyl, —N(R6)—C1-C3 alkyl-N(R6)2, —O—C1-C3 alkyl-N(R6)2, and —N(R6)—C1-C3 alkyl-OR6, wherein cycloalkyl and heterocycloalkyl are optionally substituted by one or more R5.

### Claim 10 (depends on 6, 7, 8, 9)

The compound of anyone of claims 6-9, wherein the compound of Formula III is selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

A pharmaceutical composition comprising a compound of any of claims 1-10, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

A method of inhibiting the activity of HDAC1 and/or HDAC2 in a subject of need thereof, comprising administering to the subject a therapeutically effective amount of a compound of any of claims 1-10, or the pharmaceutical composition of claim 11.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

A method of treating a disease mediated by HDAC1 and/or HDAC2 in a subject of need thereof, comprising administering to the subject a therapeutically effective amount of a compound of any of claims 1-10, or the pharmaceutical composition of claim 11.

### Claim 14 (depends on 13)

The method of claim 13, wherein the disease is a myelodysplastic syndrome.

### Claim 15 (depends on 13)

The method of claim 13, wherein the disease is a hemoglobinopathy.

### Claim 16 (depends on 15)

The method of claim 15, wherein the hemoglobinopathy is a sickle-cell disease.

### Claim 17 (depends on 15)

The method of claim 15, wherein the hemoglobinopathy is beta-thalassemia.

### Claim 18 (depends on 13)

The method of claim 13, wherein the disease is alopecia, spinal muscular atrophy, inflammatory bowel disease, or Crohn's ulcerative colitis.

### Claim 19 (depends on 13)

The method of claim 13, wherein the disease is diabetes.

### Claim 20 (depends on 13)

The method of claim 13, wherein the disease is hearing loss.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

A method of treating cancer in a subject of need thereof, comprising administering to the subject a therapeutically effective amount of a compound of any of claims 1-10, or the pharmaceutical composition of claim 11.

### Claim 22 (depends on 21)

The method of claim 21, wherein the cancer is lung cancer, colon cancer, or breast cancer.

### Claim 23 (depends on 21)

The method of claim 21, wherein the cancer is neuroblastoma, leukemia, or lymphoma.

### Claim 24 (depends on 21)

The method of claim 21, wherein the cancer is acute myelogenous leukemia or acute megakaryocytic leukemia.

### Claim 25 (depends on 21)

The method of claim 21, wherein the cancer is neuroblastoma.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

A method of treating diabetes in a subject of need thereof, comprising administering to the subject a therapeutically effective amount of a compound of any of claims 1-10, or the pharmaceutical composition of claim 11.

### Claim 27 (depends on 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)

The method of any of claims 12-26, wherein the subject is human.
